Pergolide

Base Information

• Chemical Name: Pergolide
• CAS No.: 66104-22-1
• Molecular Formula: C₁₉H₂₆N₂S
• Molecular Weight: 314.495
• European Community (EC) Number: 811-107-4
• UNII: 24MJ822NZ9
• DSSTox Substance ID: DTXSID2023438
• Nikkaji Number: J19.083G
• Wikipedia: Pergolide
• Wikidata: Q415752
• NCI Thesaurus Code: C61886
• RXCUI: 8047
• Pharos Ligand ID: 8YM58YPXL71B
• Metabolomics Workbench ID: 43402
• ChEMBL ID: CHEMBL531
• Mol file: 66104-22-1.mol

Synonyms:Celance;LY-127,809;LY-127809;LY127,809;LY127809;Mesylate, Pergolide;Parkotil;Pergolide;Pergolide Mesylate;Permax;Pharken

Chemical Property of Pergolide

Chemical Property:

• Vapor Pressure: 8.5E-10mmHg at 25°C
• Melting Point: 207.5 °C
• Boiling Point: 491.3 °C at 760 mmHg
• PKA: 17.66±0.40(Predicted)
• Flash Point: 250.9 °C
• PSA: 44.33000
• Density: 1.124 g/cm³
• LogP: 4.20900
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• XLogP3: 4.2
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 2
• Rotatable Bond Count: 4
• Exact Mass: 314.18167001
• Heavy Atom Count: 22
• Complexity: 388

Purity/Quality:

98%,99%, ^*data from raw suppliers

Pergolide ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antiparkinson Agents
• Canonical SMILES: CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC
• Isomeric SMILES: CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC
• Recent ClinicalTrials: Dose Response Trial of Pergolide for Cocaine Dependence - 1
• Recent EU Clinical Trials: Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un dispositif médical
• Uses: dopamine receptor agonist, anti-Parkinson's agent
• Therapeutic Function: Dopamine agonist
• Clinical Use: Pergolide is a nonpeptide ergot derivative with higher potency and efficacy as a D1 agonist and equivalent D2 agonist activity when compared to bromocriptine. For Parkinson's disease, as well as for inhibition of lactation, pergolide is more potent than bromocriptine and may be effective in patients who have become tolerant to bromocriptine. After oral administration, pergolide undergoes hepatic metabolism to 10 metabolites, some of which are pharmacologically active. Elimination of the drug is primarily renal, with a half-life is approximately 27 hours.
• Drug interactions: Potentially hazardous interactions with other drugs None known

Technology Process of Pergolide

There total 10 articles about Pergolide which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 68.0%

NaOH(aq) + D-1,6-dipropionyl-8β(methylthiomethyl)ergoline → pergolide (66104-22-1)

Guidance literature:

With lithium aluminium tetrahydride; In tetrahydrofuran; water;

Reference yield: 52.0%

→ pergolide (66104-22-1)

Guidance literature:

Reference yield: 6.53%

D-6-propyl-8β-mesyloxymethylergoline (72821-83-1) + sodium thiomethoxide (5188-07-8) → pergolide (66104-22-1)

Guidance literature:

In N,N-dimethyl-formamide; at 20 ℃; for 2h;

DOI:10.1039/b104843k

upstream raw materials:

D-6-propyl-8β-mesyloxymethylergoline

sodium thiomethoxide

D-6-propyl-8β-hydroxymethylergoline

9,10-dihydrolysergol

Downstream raw materials:

pergolide sulfoxide

pergolide sulfone

pergolide mesylate

Refernces

• 1、 -. "Process for preparing pergolide". . . Retrieved 2008/06/13.
• 2、 -. "Decyanation of pergolide intermediate". . . Retrieved 2008/06/13.